DOS PREMIOS DOTADOS CON 3.000 EUR cada uno al mejor trabajo de investigación publicado en revistas nacionales o internacionales durante el año 2010, en temas relacionados con politraumatismos, trasplante de órganos, oncologí­a médico-quirúrgica y cualquier otro relacionado con las ciencias médicas.
Noticia completa

Un estudio realizado en Italia marca otro avance hacia a la creación de una retina artificial orgánica, eléctricamente autónoma y con una eficiencia comparable a la humana.
El trabajo para la puesta a punto del prototipo, con la autorí­a del Departamento de neurociencias y neurotecnologí­as (NBT) del Centro de nano-ciencias y tecnologí­as del Instituto italiano de Tecnologí­a (CNST – IIT) y del Departamento de fí­sica del Politécnico de Milán, fue publicado ayer en la revista Nature y fue coordinado por Guglielmo Lanzni del CNST.
Noticia completa

Uno de los grandes retos en investigación biomédica es la generación de modelos animales que respondan lo más fielmente posible a las preguntas experimentales sobre enfermedades del hombre. En este contexto, el proyecto europeo Eucommtools (Herramientas para la anotación funcional del genoma del ratón) se ha convertido en la mayor iniciativa mundial para determinar la expresión del genoma del ratón y generar modelos animales de enfermedades genéticas.
Noticia completa

El ensayo examinará las posibilidades que tiene esta terapia de tratar de forma segura a personas que padecen degeneración macular relacionada a la edad, que es la forma más común de pérdida de visión irreversible en mayores de 60 años. Actualmente no existe cura para esta enfermedad que afecta a entre 10 y 15 millones de estadounidenses y a 10 millones de personas en Europa, informó la empresa.
Noticia completa

El Simposio Internacional del Sí­ndrome de Usher y Enfermedades Relacionadas, celebrado en Valencia, ha reunido a expertos de diferentes disciplinas y ámbitos de investigación para analizar la situación actual y perspectivas futuras de esta patologí­a
Noticia completa

In a study published in the Proceedings of the National Academy of Sciences, a team of researchers from the Kennedy Krieger Institute and four collaborating institutions, identified a new and unexpected biological pathway that appears to contribute to the development of glaucoma and its resulting vision loss.
Noticia completa

Cumbersome glaucoma tests that require a visit to the ophthalmologist could soon be history thanks to a home test developed by a UA engineer.
Noticia completa

University of Manchester scientists have found that a new type of light sensitive cell (photoreceptor) in the eye helps the brain measure brightness. This mechanism, which works alongside the rod and cone photoreceptors, may be important for people with certain types of blindness.

Noticia completa

Damage to the optic nerve, connecting the eye with the brain, is a major cause of blindness. The most common culprit is glaucoma, estimated to affect more than 4 million Americans. There is currently no way to restore the lost vision, because the optic nerve, like other nerves in the mature central nervous system (CNS), cannot regenerate. Now, scientists at Children’s Hospital Boston report achieving the greatest regeneration to date in the mammalian optic nerve.
Noticia completa

Novartis Pharmaceuticals UK Ltd announced that Lucentis® (ranibizumab) has launched in the UK for the treatment of visual impairment due to diabetes, specifically diabetic macular oedema (DMO). This offers fresh hope for people with this serious and common complication of diabetes.
Noticia completa

InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, has announced that patient enrollment was recently completed in the company’s Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce the pain and inflammation associated with ocular surgery. ISV-303 combines a low dose of the non-steroidal anti-inflammatory (NSAID) bromfenac (BROMDAYâ„¢/Xibromâ„¢ marketed by ISTA Pharmaceuticals) with InSite Vision’s proprietary DuraSite® technology.
Noticia completa

The inhibition or removal of an enzyme may prevent or treat ischemic retinopathy by stalling growth of unwanted vessels in the retina, Medical College of Georgia researchers say.
Noticia completa

Better known as the light sensor that sets the body’s biological clock, melanopsin also plays an important role in vision: Via its messengers-so-called melanopsin-expressing retinal ganglion cells, or mRGCs-it forwards information about the brightness of incoming light directly to conventional visual centers in the brain, reports an international collaboration of scientists in this week’s issue of PLoS Biology.
Noticia completa

There is more to the eye than rods and cones ”” the discovery of a third photoreceptor is rewriting the visual rulebook.Russell Foster remembers his first human subject, an 87-year-old woman, as she sat in a dark room facing a backlit pane of frosted glass. A genetic disorder had destroyed the light-sensing rod and cone cells in her eyes, leaving her blind for the past 50 years. She was convinced that she would see nothing. But as the wavelength of light in the room shifted to blue, she reported ”” after some hesitation ”” a sort of brightness.
Noticia completa

UK medical schools are failing to comply with the recommended curriculum for ophthalmology, set out by the International Council of Ophthalmologists (ICO), suggests a survey published online in the British Journal of Ophthalmology.
Noticia completa

Alkeus Pharmaceuticals and Columbia University announced today that they have entered into a license agreement for a set of potential therapies for the treatment of dry age-related macular degeneration (dry-AMD), Stargardt disease, and other degenerative diseases of the eye. Left untreated, these conditions often lead to impaired vision and even blindness.
Noticia completa

Advanced Cell Technology, Inc. («ACT»; OTCBB:ACTC), a leader in the field of regenerative medicine, announced that the US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to treat Dry Age-Related Macular Degeneration (AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). ACT is now permitted to initiate a Phase I/II multicenter clinical trial to treat patients with Dry AMD, the most common form of macular degeneration in the world. There are currently no treatments available for this prevalent disease of an aging global population. Dry AMD, representing a substantial global market opportunity and afflicts between 10-15 million Americans.
Noticia completa

EU-funded scientists have developed a system that releases researchers from the chore of spending hours hunched over a microscope looking for cells of interest in large samples. The system is described in the journal Nature Methods by a team led by the European Molecular Biology Laboratory (EMBL) in Germany.
Noticia completa

An implant that releases the medication dexamethasone within the eye appears safe and effective for the treatment of some types of uveitis (swelling and inflammation in the eye’s middle layer), according to a report posted online today that will appear in the May print issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
Noticia completa